MedTrace Logo

Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

NCT04693026 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-01-05

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.

Conditions

  • Covid19
  • Covid-19 ARDS

Interventions

DRUG

Remdesivir

Remdesivir 100 IV Infusion as a lyophilized powder

DRUG

Baricitinib

Baricitinib oral tablet form

DRUG

Tocilizumab

Tocilizumab IV Infusion

Sponsors & Collaborators

  • First affiliated Hospital Xi'an Jiaoting University

    collaborator UNKNOWN

  • M Abdur Rahim Medical College and Hospital

    lead OTHER_GOV

Principal Investigators

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

  • Akter Kamal, MD, PhD · M Abdur Rahim Medical College and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2021-02-15
Completion
2021-03-05

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693026 on ClinicalTrials.gov